Genprex, Inc.

Genprex (Nasdaq: $GNPX) is a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes.

[Genprex, Inc. @genprex]

A few members from the Genprex team attended #ASCO2026 this week where our collaborators' abstract was published detailing positive clinical data from studies of predictive biomarkers in patients receiving Reqorsa® for the treatment of #lungcancer.

[Genprex, Inc. @genprex]

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting: https://t.co/xVtsiEFGX1 #ASCO #LungCancer

[Genprex, Inc. @genprex]

Our research collaborators presented positive preclinical data on our diabetes gene therapy at the 2026 ASGCT Annual Meeting. The poster can be reviewed in detail by clicking here: https://t.co/Icj79jU9wp #Diabetes #Type2 #GeneTherapy

[Genprex, Inc. @genprex]

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting: https://t.co/ugqqz4gagA #GeneTherapy #Diabetes

[Genprex, Inc. @genprex]

Genprex was featured in Cure's Member Spotlight series, where they highlight the groundbreaking work of the companies and individuals in Cure’s community. Check out the Q&A with Genprex's President and CEO here: https://t.co/VzGOCrBny9 #GeneTherapy #LungCancer #Diabetes

[Genprex, Inc. @genprex]

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer: https://t.co/PgcuP1RpWz #GeneTherapy #LungCancer

[Genprex, Inc. @genprex]

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting: https://t.co/bkaHY1S4U2 #Diabetes #GeneTherapy

[Genprex, Inc. @genprex]

Genprex collaborators presented preclinical data at #AACR26 in a poster, titled, "Restoring TUSC2 function boosts NK cell cytotoxicity and antitumor immunity in vivo and in vitro." To view the poster, click here: https://t.co/fPlHgHUpG9 #GeneTherapy $GNPX

[Genprex, Inc. @genprex]

$GNPX Collaborators presented preclinical data on Reqorsa Gene Therapy in EML4-ALK bearing NSCLC at #AARC26. Read the poster in more detail here: https://t.co/HL17NzHHlS #LungCancer #GeneTherapy

[Genprex, Inc. @genprex]

$GNPX's Chief Medical Officer, Mark Berger, MD, poses with one of our collaborators at the #AACR26 conference. To view the poster, "TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy" in more detail, click here: https://t.co/CLCEbJCGzH #LungCancer

[Genprex, Inc. @genprex]

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting: https://t.co/MXpXguL46u #LungCancer #GeneTherapy

[Genprex, Inc. @genprex]

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy: https://t.co/k0SBfSuh50 #lungcancer #tailoredtreatment #genetherapy

[Genprex, Inc. @genprex]

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting: https://t.co/rWrbO0aFZY #AACR #LungCancer #GeneTherapy #Oncology

[Genprex, Inc. @genprex]

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting: https://t.co/7lBxcmgS0J #lungcancer #genetherapy

[Genprex, Inc. @genprex]

Genprex to Participate at BIO Europe Spring 2026: https://t.co/NmtVZA80aG #Oncology #Diabetes #GeneTherapy $GNPX

[Genprex, Inc. @genprex]

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer: https://t.co/DaMqDAFW0R

[Genprex, Inc. @genprex]

Genprex Announces IP Australia’s Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers: https://t.co/ConWn2Eeh0 #genetherapy #lungcancer

[Genprex, Inc. @genprex]

Genprex recently announced positive preliminary preclinical data in Type 2 diabetes. Watch this video featuring Genprex's CEO and CMO discussing the new data and what it means: https://t.co/pmYoVmdAat #genetherapy #diabetes #video $GNPX

[Genprex, Inc. @genprex]

Genprex Provides Clinical Update on Diabetes Gene Therapy Program: https://t.co/W2XBH1VSJH #genetherapy #diabetes $GNPX

[Genprex, Inc. @genprex]

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies: https://t.co/UPdxuFaaV8 #genetherapy #diabetes $GNPX